A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland. / Thuesen, Anne Cathrine Baun; Stæger, Frederik Filip; Kaci, Alba; Solheim, Marie Holm; Aukrust, Ingvild; Jørsboe, Emil; Santander, Cindy G.; Andersen, Mette K.; Li, Zilong; Gilly, Arthur; Stinson, Sara Elizabeth; Gjesing, Anette Prior; Bjerregaard, Peter; Pedersen, Michael Lynge; Larsen, Christina Viskum Lytken; Grarup, Niels; Jørgensen, Marit E.; Zeggini, Eleftheria; Bjørkhaug, Lise; Njølstad, Pål Rasmus; Albrechtsen, Anders; Moltke, Ida; Hansen, Torben.

In: The Lancet Regional Health - Europe, Vol. 24, 100529, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Thuesen, ACB, Stæger, FF, Kaci, A, Solheim, MH, Aukrust, I, Jørsboe, E, Santander, CG, Andersen, MK, Li, Z, Gilly, A, Stinson, SE, Gjesing, AP, Bjerregaard, P, Pedersen, ML, Larsen, CVL, Grarup, N, Jørgensen, ME, Zeggini, E, Bjørkhaug, L, Njølstad, PR, Albrechtsen, A, Moltke, I & Hansen, T 2023, 'A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland', The Lancet Regional Health - Europe, vol. 24, 100529. https://doi.org/10.1016/j.lanepe.2022.100529

APA

Thuesen, A. C. B., Stæger, F. F., Kaci, A., Solheim, M. H., Aukrust, I., Jørsboe, E., Santander, C. G., Andersen, M. K., Li, Z., Gilly, A., Stinson, S. E., Gjesing, A. P., Bjerregaard, P., Pedersen, M. L., Larsen, C. V. L., Grarup, N., Jørgensen, M. E., Zeggini, E., Bjørkhaug, L., ... Hansen, T. (2023). A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland. The Lancet Regional Health - Europe, 24, [100529]. https://doi.org/10.1016/j.lanepe.2022.100529

Vancouver

Thuesen ACB, Stæger FF, Kaci A, Solheim MH, Aukrust I, Jørsboe E et al. A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland. The Lancet Regional Health - Europe. 2023;24. 100529. https://doi.org/10.1016/j.lanepe.2022.100529

Author

Thuesen, Anne Cathrine Baun ; Stæger, Frederik Filip ; Kaci, Alba ; Solheim, Marie Holm ; Aukrust, Ingvild ; Jørsboe, Emil ; Santander, Cindy G. ; Andersen, Mette K. ; Li, Zilong ; Gilly, Arthur ; Stinson, Sara Elizabeth ; Gjesing, Anette Prior ; Bjerregaard, Peter ; Pedersen, Michael Lynge ; Larsen, Christina Viskum Lytken ; Grarup, Niels ; Jørgensen, Marit E. ; Zeggini, Eleftheria ; Bjørkhaug, Lise ; Njølstad, Pål Rasmus ; Albrechtsen, Anders ; Moltke, Ida ; Hansen, Torben. / A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland. In: The Lancet Regional Health - Europe. 2023 ; Vol. 24.

Bibtex

@article{82baefb4002f4242bba39122f074ca79,
title = "A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland",
abstract = "Background: The genetic disease architecture of Inuit includes a large number of common high-impact variants. Identification of such variants contributes to our understanding of the genetic aetiology of diseases and improves global equity in genomic personalised medicine. We aimed to identify and characterise novel variants in genes associated with Maturity Onset Diabetes of the Young (MODY) in the Greenlandic population. Methods: Using combined data from Greenlandic population cohorts of 4497 individuals, including 448 whole genome sequenced individuals, we screened 14 known MODY genes for previously identified and novel variants. We functionally characterised an identified novel variant and assessed its association with diabetes prevalence and cardiometabolic traits and population impact. Findings: We identified a novel variant in the known MODY gene HNF1A with an allele frequency of 1.9% in the Greenlandic Inuit and absent elsewhere. Functional assays indicate that it prevents normal splicing of the gene. The variant caused lower 30-min insulin (β = −232 pmol/L, βSD = −0.695, P = 4.43 × 10−4) and higher 30-min glucose (β = 1.20 mmol/L, βSD = 0.441, P = 0.0271) during an oral glucose tolerance test. Furthermore, the variant was associated with type 2 diabetes (OR 4.35, P = 7.24 × 10−6) and HbA1c (β = 0.113 HbA1c%, βSD = 0.205, P = 7.84 × 10−3). The variant explained 2.5% of diabetes variance in Greenland. Interpretation: The reported variant has the largest population impact of any previously reported variant within a MODY gene. Together with the recessive TBC1D4 variant, we show that close to 1 in 5 cases of diabetes (18%) in Greenland are associated with high-impact genetic variants compared to 1–3% in large populations. Funding: Novo Nordisk Foundation, Independent Research Fund Denmark, and Karen Elise Jensen's Foundation.",
author = "Thuesen, {Anne Cathrine Baun} and St{\ae}ger, {Frederik Filip} and Alba Kaci and Solheim, {Marie Holm} and Ingvild Aukrust and Emil J{\o}rsboe and Santander, {Cindy G.} and Andersen, {Mette K.} and Zilong Li and Arthur Gilly and Stinson, {Sara Elizabeth} and Gjesing, {Anette Prior} and Peter Bjerregaard and Pedersen, {Michael Lynge} and Larsen, {Christina Viskum Lytken} and Niels Grarup and J{\o}rgensen, {Marit E.} and Eleftheria Zeggini and Lise Bj{\o}rkhaug and Nj{\o}lstad, {P{\aa}l Rasmus} and Anders Albrechtsen and Ida Moltke and Torben Hansen",
note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2023",
doi = "10.1016/j.lanepe.2022.100529",
language = "English",
volume = "24",
journal = "The Lancet Regional Health - Europe",
issn = "2666-7762",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - A novel splice-affecting HNF1A variant with large population impact on diabetes in Greenland

AU - Thuesen, Anne Cathrine Baun

AU - Stæger, Frederik Filip

AU - Kaci, Alba

AU - Solheim, Marie Holm

AU - Aukrust, Ingvild

AU - Jørsboe, Emil

AU - Santander, Cindy G.

AU - Andersen, Mette K.

AU - Li, Zilong

AU - Gilly, Arthur

AU - Stinson, Sara Elizabeth

AU - Gjesing, Anette Prior

AU - Bjerregaard, Peter

AU - Pedersen, Michael Lynge

AU - Larsen, Christina Viskum Lytken

AU - Grarup, Niels

AU - Jørgensen, Marit E.

AU - Zeggini, Eleftheria

AU - Bjørkhaug, Lise

AU - Njølstad, Pål Rasmus

AU - Albrechtsen, Anders

AU - Moltke, Ida

AU - Hansen, Torben

N1 - Publisher Copyright: © 2022 The Author(s)

PY - 2023

Y1 - 2023

N2 - Background: The genetic disease architecture of Inuit includes a large number of common high-impact variants. Identification of such variants contributes to our understanding of the genetic aetiology of diseases and improves global equity in genomic personalised medicine. We aimed to identify and characterise novel variants in genes associated with Maturity Onset Diabetes of the Young (MODY) in the Greenlandic population. Methods: Using combined data from Greenlandic population cohorts of 4497 individuals, including 448 whole genome sequenced individuals, we screened 14 known MODY genes for previously identified and novel variants. We functionally characterised an identified novel variant and assessed its association with diabetes prevalence and cardiometabolic traits and population impact. Findings: We identified a novel variant in the known MODY gene HNF1A with an allele frequency of 1.9% in the Greenlandic Inuit and absent elsewhere. Functional assays indicate that it prevents normal splicing of the gene. The variant caused lower 30-min insulin (β = −232 pmol/L, βSD = −0.695, P = 4.43 × 10−4) and higher 30-min glucose (β = 1.20 mmol/L, βSD = 0.441, P = 0.0271) during an oral glucose tolerance test. Furthermore, the variant was associated with type 2 diabetes (OR 4.35, P = 7.24 × 10−6) and HbA1c (β = 0.113 HbA1c%, βSD = 0.205, P = 7.84 × 10−3). The variant explained 2.5% of diabetes variance in Greenland. Interpretation: The reported variant has the largest population impact of any previously reported variant within a MODY gene. Together with the recessive TBC1D4 variant, we show that close to 1 in 5 cases of diabetes (18%) in Greenland are associated with high-impact genetic variants compared to 1–3% in large populations. Funding: Novo Nordisk Foundation, Independent Research Fund Denmark, and Karen Elise Jensen's Foundation.

AB - Background: The genetic disease architecture of Inuit includes a large number of common high-impact variants. Identification of such variants contributes to our understanding of the genetic aetiology of diseases and improves global equity in genomic personalised medicine. We aimed to identify and characterise novel variants in genes associated with Maturity Onset Diabetes of the Young (MODY) in the Greenlandic population. Methods: Using combined data from Greenlandic population cohorts of 4497 individuals, including 448 whole genome sequenced individuals, we screened 14 known MODY genes for previously identified and novel variants. We functionally characterised an identified novel variant and assessed its association with diabetes prevalence and cardiometabolic traits and population impact. Findings: We identified a novel variant in the known MODY gene HNF1A with an allele frequency of 1.9% in the Greenlandic Inuit and absent elsewhere. Functional assays indicate that it prevents normal splicing of the gene. The variant caused lower 30-min insulin (β = −232 pmol/L, βSD = −0.695, P = 4.43 × 10−4) and higher 30-min glucose (β = 1.20 mmol/L, βSD = 0.441, P = 0.0271) during an oral glucose tolerance test. Furthermore, the variant was associated with type 2 diabetes (OR 4.35, P = 7.24 × 10−6) and HbA1c (β = 0.113 HbA1c%, βSD = 0.205, P = 7.84 × 10−3). The variant explained 2.5% of diabetes variance in Greenland. Interpretation: The reported variant has the largest population impact of any previously reported variant within a MODY gene. Together with the recessive TBC1D4 variant, we show that close to 1 in 5 cases of diabetes (18%) in Greenland are associated with high-impact genetic variants compared to 1–3% in large populations. Funding: Novo Nordisk Foundation, Independent Research Fund Denmark, and Karen Elise Jensen's Foundation.

U2 - 10.1016/j.lanepe.2022.100529

DO - 10.1016/j.lanepe.2022.100529

M3 - Journal article

C2 - 36649380

AN - SCOPUS:85145449746

VL - 24

JO - The Lancet Regional Health - Europe

JF - The Lancet Regional Health - Europe

SN - 2666-7762

M1 - 100529

ER -

ID: 331863751